Venetoclax combination safety check for CLL patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a potential side effect called hemolytic syndrome (where the body destroys its own red blood cells) in patients with chronic lymphocytic leukemia (CLL) who are treated with a drug called venetoclax combined with another therapy. It aims to make sure this treatment is safe and to better understand the risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
- You need to meet the standard criteria for starting treatment for CLL.
- You must be planning to take venetoclax with either a BTK inhibitor (like ibrutinib) or with obinutuzumab.
- You may be receiving this as your first treatment or after a relapse.
- You cannot have an active, uncontrolled infection or have cancer spread to the brain or spinal cord.
- You must not be pregnant or breastfeeding.
- You must be able to have contrast-enhanced CT scans (so no severe kidney problems or contrast allergies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Hear when a new Chronic Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.